Announcements Trials
Browse Landscape

Status

Completed 5Recruiting 2Approved for marketing 1Active not recruiting 1

Sponsor Class

OTHER 6INDUSTRY 2

Study Type

Observational 2

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion 1Advanced or Recurrent Solid Tumor Harboring an NTRK Gene Fusion 1

Interventions

pembrolizumab 241Carboplatin 167Injections 138Paclitaxel 119Gemcitabine 116Bevacizumab 112Cisplatin 105Docetaxel 82Cyclophosphamide 78Pemetrexed 76Capecitabine 69Fluorouracil 67Oxaliplatin 65Fulvestrant 57fludarabine 55Nivolumab 55Leucovorin 52Cetuximab 52130-nm albumin-bound paclitaxel 47Dexamethasone 46Rituximab 41atezolizumab 37venetoclax 35Drug Therapy 35toripalimab 34enzalutamide 34Irinotecan 34durvalumab 32Prednisone 32Letrozole 32

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × INDUSTRY × larotrectinib × Clear all
NCT04142437 2026-04-14

ON-TRK

Bayer

Recruiting
150 enrolled
Other solid neoplasm

Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion

NCT04945330 2026-04-14

NTRK Gene Fusion - Positive Advanced or Recurrent Solid Tumors, a Rare Cancer Caused by Specific Changes in the Genes

Bayer

Recruiting
100 enrolled
Other solid neoplasm

Advanced or Recurrent Solid Tumor Harboring an NTRK Gene Fusion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡